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ABSTRACT 
Objective: The use of the classical approach of analytical validation, in practice or in the literature, is common. However, statistical verification, that 
looks separately the two errors (such as bias and precision) to make a decision, presents a risk to declare that an analytical method is valid while it 
is not, or conversely. To minimize this risk, a new approach based on the concept of total error was proposed.  
Methods: This approach proposes a calculation the two sided tolerance interval by combining the two errors; bias and precision, in order to 
examine the validity of an analytical and bioanalytical method at each concentration level. In this paper, we aim to demonstrate the applicability and 
simplicity of the both methods based on the total error approach: accuracy profile and uncertainty profile. This study will be illustrated by 
validation case of a spectrophotometric method for the determination of trace amounts of acetaminophen in human plasma.  
Results: After the introduction of the correction coefficient which is worth 1.16, the results obtained with accuracy profile approach show clearly 
that the bioanalytical method is valid over a concentrations range of [100.34- 500] µg mL-1 since the upper and lower 90%-expectation tolerance 
limits have fallen within the two acceptance limits of ± 20%. The same results found using the uncertainty profile approach because the "two - sided 
66.7%-content, 90% -confidence tolerance intervals "are found within two acceptance limits of ± 20% over the range of [170; 500] µm mL-1. 
Conclusion: The excellence of the total error approach was showen since it enables successfully to validate the analytical procedure as well the 
calculation of the measurement uncertainty at each concentration level. 
Keywords: Error total, Analytical validation, Uncertainty profile, Accuracy profile, Measurement uncertainty, Bioanalytical method.  
 
INTRODUCTION 
Every day, thousands of results are provided by several analytical 
and bioanalytical methods. These analytical results are intended for 
an envisaged use in various sectors (chemical, biochemical, 
pharmaceutical, environment..) on behalf of customers who expect 
to be able to trust the results reported. Such confidence should be 
maintained by providing material and scientific proofs by the 
supplier, notably the laboratory, to justify and ensure the reliability 
of these results. Indeed, view of the importance of the decisions, 
such as compliance with government regulations or limits to set in 
international trade, it is important to prove the reliability of these 
results. This amounts to demonstrate suitability for the use of 
analytical methods [1]. 
In such context, many standards and guidelines require the 
application of validated and verified analytical methods including 
FDA, ICH and ISO / IEC 17025, since that a validation is the set of 
operations performed in order to prove that a procedure is 
sufficiently accurate and reliable to have confidence in the results 
provided for the intended purpose (of the assay method) [2-5]. 
Furthermore, most guidelines suggest the use of conventional 
approaches of validation based on hypothesis test H0 using a colossal 
number of statistical tests to check all validation criteria. These statistical 
tests aim to verify separately the two characteristic errors of the method 
such as bias and precision. In this way, the risk of accepting a precise and 
unbiased method or reject a true method that is not precise is likely [6]. 
This means that decision making is not consistent with the objective of 
an analytical method. Since the objective of a good analysis procedure is 
to be able to quantify as accurately as possible each unknown quantities 
that the laboratory should determine. 
In other words, good analytical procedure is the one, when it’s 
applied; we will get an accepted probability that the difference, 
between each measured value (x) of a sample and its actual value 
(μ), will be within the acceptable limits, according to the following 
relationship: 𝑃𝑃𝑃𝑃(|𝑥𝑥 − µ| < 𝜆𝜆) ≥ 𝛽𝛽[7-9]. 
In order to make a correct decision, the two errors (bias and 
precision), peculiar to each analytical method, are combined to 
calculate a two sided tolerance interval according to the Mee's 
proposal. Indeed, Mee have successfully developed two types of 
tolerance interval that shows their effectiveness to be used for 
quality measurement [12]: 
1- β- expectation tolerance interval, (β-ETI). 
2- β-content, γ-confidence tolerance interval, (β, γ-CTI). 
Hubert and al. has succeeded by using (β-IT) to develop the accuracy 
profile as a simple and powerful tool for decision making with respect 
to the method validation [9-11]. In this graphical tool, it have 
combined two sided β-tolerance intervals and the acceptance limits 
along the studied concentration range. If these two tolerance intervals 
fall within the two acceptable limits, the method is declared valid. 
Recently, Saffaj and Ihssane have developed a new approach based 
on the calculation of measurement uncertainty using (β, γ -CTI), 
called the uncertainty profile as a powerful tool for the validation of 
the analytical method [13-16].  
The uncertainty profile has also shown its capacity and efficiency by 
applying it on a set of the chromatographic method for the 
determination of analytes in chemical matrix as well as in biological 
matrix [16, 17]. 
The main objective of this paper is to verify the validity of the 
determination method of trace amounts of acetaminophen in human 
plasma using two chemometric approaches (the β- expectation 
tolerance interval and the β-content, γ-confidence tolerance 
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interval). We try to show the applicability of total error approach: 
accuracy profile and uncertainty profile as the powerful tool to 
assess the performance the bioanalytical spectrometric method and 
its suitability for use in routine control. 
MATERIALS AND METHODS 
Reagents 
All the experiments were performed with analytical-reagent grade 
chemicals and pure solvents. Deionized water was used to prepare 
all solution and all experiments. 
Solutions 
Accurately weighed (100 mg) of ACP was transferred and dissolved 
in a 100 ml standard flasks. Solution was stable for at least 1 week. 
Working solutions were obtained by appropriate dilution with 
deionised water. 
A 10% trichloroacetic acid solution was prepared in amber-glass 
volumetric flasks. A 20% sodium nitrite solution, a 30% sulfamic acid 
solution, 6M HCl and 25% sodium hydroxide solution were prepared 
separately in deionised water in amber-glass volumetric flasks. 
Apparatus  
A JASCO UV-visible spectrophotometer type V530 with Band width: 
2.0 nm. Measurement range: 1000-200 nm and data pitch: 1 nm was 
used 
Basic procedure 
In glass centrifuge tubes of 10 ml, 1 ml of plasma standard, 0-400 µL 
of Acetaminophen and 2 ml of 10% trichloroacetic acid solution 
were added and a quantity of deionised water was added to 
complete 4 ml. After vortex mixing for 1 min. 1 ml of 6M HCl and 2 
ml of NaNO2 were added with swirling. The solutions were allowed 
to stand for 5 min and then 2 ml of 30% sulfamic acid solution was 
added. The solutions were swirled again and allowed to stand for 5 
min. Add 2 ml of 25% NaOH and in vortex mix for 30 seconds. A 
reagent blank solution was prepared in a similar way. The 
absorbance at 430 nm was measured against the reagent blank. 
After addition of trichloroacetic acid, proteins defecation occur. In 
acid medium, the presence of nitrous acid leads to the 
transformation of Acetaminophen in a nitrous derivative which is 
colored in yellow-orange in alkaline medium. The stochiometric 


















Fig. 1: Proposed mechanism of reaction of determination of Acetaminophen 
 
Pre-validation study 
Validity of the Beer-Lambert law 
The determination of the concentration range wherein the Beer-
Lambert law is checked depends on the quality of the linear 
regression between the absorbance and concentrations. Indeed, in 
order to avoid the effect of parasite light, we look for the 
concentration range in which the coefficient of determination R² 
which represents the quality of explanatory right fit to be close to 1. 
Matrix effect 
The main cause of a lack of specificity is the presence of interference. 
Interference is a major contributor of inaccuracy. When it comes to the 
specificity and interference, systematic errors that occur, are directly 
related to the method and contribute to the final budget of uncertainty. 
Interference sources are also due to the presence of constituents of the 
matrix generally unknown, known as matrix effects. In practice, the 
interference has two negative consequences. They lead an 
overestimation of the concentration of the sample, because the analytical 
response is greater than it should be; or they cause an underestimation 
of the concentration, because the signal is partially masked. 
Let Xj is the concentration introduced and Zj is the calculated 
concentration by inverse calibration. If we plot the calculated 
concentrations versus introduced concentrations three different 
situations occur: (1) equation Z = X is obtained meaning absence of 
the matrix effect, (2) equation Z = b1X is achieved indicating 
presence of the multiplicative effect and (3) equation Z = b0X is 
produced signifying the presence of the additive effect. One might 
think that there is another situation where the past two effects were 
combines called combined effect: Z = b0 + b1X. 
Thus, the coefficient b1, slope of the equation of the straight, can be 
likened to an inverse average recovery rate, as defined in the 
literature. This rate is regarded as a correction factor on the results 
which present a lack of exactitude [18]. 
Validation using total error approach 
In order to check the validity of the bioanalytical method, we 
propose in this paper the use of two chemometrics approaches such 
as the accuracy profile approach using β-expectation tolerance 
interval and uncertainty profile approach developed in our 
laboratory, and based on the use of β,γ-content tolerance interval. 
Furthermore, to complete the interpretation of the results 
performed by this method and judge its capability to provide 
accurate measurements, uncertainty is estimated at each 
concentration level. Uncertainty values calculated are compared 
with the acceptance limits. 
We note that the both concepts of an accuracy profile and 
uncertainty profile were based on the selection of the appropriate 
regression model for calibration.  
Several documents in the literature introduce and explain the total error 
approach [10, 11, 19-25]. We can summarize it in the following steps:  
Select the suitable model 
The series of calibration standards prepared using material reference 
(SMR) help to generate many regression models for calibration, e. g. 
simple linear regression, weighted simple regression, quadratic 
regression, weighted quadratic regression, logarithmic 
transformation, square root transformation.. We will then select the 
most suitable model that allows a good inverse prediction.  
Inverse prediction 
The inverse prediction performed via the selected model gives the 
retrieved concentrations, denoted Zj  for each concentration level. 
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Table 1: Some examples of formulas of calculation of the inverse prediction 
Model Inverse prediction formula 
straight regression through origin 𝑍𝑍𝑗𝑗 =
𝑦𝑦𝑗𝑗
𝑏𝑏1�  
























Estimation of trueness 
The trueness of a bioanalytical method (or bias) at each 
concentration level is obtained by calculating the difference between 
the introduced concentrations mean (Xj) and the calculated 
concentrations mean ((Zj). The bias can be expressed in absolute or 
relative terms or in recovery terms, compared to the introduced 
concentration and was assessed from the validation standards in the 




Recovry (%) = zi/xi × 100 Eq.2 
Estimation of precision 
The precision of a bioanalytical procedure is usually expressed as 
the variance, standard deviation or coefficient of variation of a series 
of measurements. In the present study, no data is missed; therefore 
the repeatability and intermediate precision can be evaluated at 
each level of concentration using one way analysis of variance (one 
way ANOVA). Indeed, two main variances are estimated, within-
series variance Sw2  and between-series variance SB2 . A statistical 
model to describe the measured values is given by:  
yij = μ + bi + eij; j = 1,2, … , n;  i = 1,2, … , a  
Where Yij denote the jth replicate observation corresponding to ith 
run, µ is an unknown general mean, bi’ s represent random effects 
and eij’s represent error terms. It is assumed that bi’s and eij’s are all 
independent having the distributions bi~ N(0, σb2) and eij~ N(0, σe2). 
Thus,yij~ N(0, σb
2 + σe2) and σb2 and σe2 represent the two variance 







































(MSb − MSe) and Se
2 = MSe 
 
If    MSe < MSb; 
The repeatability and intermediate precision will respectively:  




2 = 0 and S𝑝𝑝I = ST 
Where,S  T
2  was the total variance of the set of measures. 
Accuracy profile method 
Estimation of β-expectation tolerance interval 
The accuracy is the total error linked to the result which combines 
the systematic error and the random errors that are related to the 
test result. The accuracy is expressed as a tolerance interval. Using 
the parameters calculated previously; bias (%), Sw
2 , SB
2 and RSDPI the 
lower and the upper (Lj, Uj) β-expectation tolerance limits are 
calculated as follows:  
𝐋𝐋𝐣𝐣 = 𝐛𝐛𝐛𝐛𝐛𝐛𝐛𝐛(%) − 𝐭𝐭(𝛖𝛖,𝟏𝟏+𝛃𝛃 𝟐𝟐⁄ )�𝟏𝟏+
𝟏𝟏
𝐩𝐩𝐩𝐩𝐁𝐁𝐣𝐣
𝟐𝟐  𝐑𝐑𝐑𝐑𝐑𝐑𝐏𝐏𝐏𝐏Eq.4 
𝐔𝐔𝐣𝐣 = 𝐛𝐛𝐛𝐛𝐛𝐛𝐛𝐛(%) + 𝐭𝐭(𝛖𝛖,𝟏𝟏+𝛃𝛃 𝟐𝟐⁄ )�𝟏𝟏+
𝟏𝟏
𝐩𝐩𝐩𝐩𝐁𝐁𝐣𝐣
𝟐𝟐  𝐑𝐑𝐑𝐑𝐑𝐑𝐏𝐏𝐏𝐏Eq.5 
Where 𝐭𝐭(𝛖𝛖.𝟏𝟏+𝛃𝛃 𝟐𝟐⁄ ) is the quantile of the Student t distribution with 𝛖𝛖 
degrees of freedom, where p is the number of series, n the number 
of replicates for the validation standards and 
Bj2 = (Rj + 1) (nRJ + 1)�  with Rj = SB
2 SW
2⁄  Was calculated at jth 
concentration level. 
Construction of accuracy profile  
Accuracy profile is a decision-making graphical tool aiming to help 
the analyst in deciding whether a bioanalytical procedure is valid. It 
is based on the combination in the same graphic of the tolerance 
interval and the acceptability limits. Two modes of representation of 
the accuracy profile are possible. The first is to express all results in 
relative values returned to the reference value level. Acceptability 
limits are also expressed as relative. Second is to express the results 
(accuracy, precision, tolerance interval and limits of acceptability) as 
an error. 
Each method can be considered as accurate over the concentration 
range investigated, as long as the upper and lower β-expectance 
limits did not exceeded the acceptance limits settled at ±λ for each 
concentration level. 
Uncertainty profile method 
Uncertainty profile approach was developed by Saffaj and Ihssane in 
[13,16]. In this paper, we aim to demonstrate the applicability and 
capability of our approach to validate and demonstrate the 
performance of a bioanalytical method. 
In order to calculate the uncertainty for each concentration level, we 
needed to calculate the upper and lower β-content, γ-confidence 
tolerance interval. 
To construct a two-sided β-content, γ-confidence tolerance interval, 
in this work we have using Mee's approach. The (β, γ) two-sided 
tolerance interval is assumed to be of the form [13, 16]: 
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2 are the estimates of the reproducibility variance, the 
between conditions variance and the within conditions variance 
(repeatability). 
Mee uses the Satterthwaite approximation to get an approximate 
Chi-square distribution associated with σ�m2 . The two sided β-content 
tolerance interval under this method takes the following form:  















R =  
σb2
σe2










2 (h) denotes the β quantile of a noncentral chi-square 
distribution with degrees of freedom ν and noncentrality parameter 
h.  
• a is the number of series. 





According to the demonstration of Saffaj et al. [13], the uncertainty 
can be determined from validation data using such the upper and 
lower β- content tolerance interval (β-CTI).  
In Ref. [16], we have showed that for calculating the uncertainty of 
analytical measurements, it is doable and preferable that one should 





 Eq. 12 
Where Uj is the upper β-CTI; Lj  is the lower β-CTI, t(ν) is the (1 + 
γ)/2 quantile of Student t distribution with ν degrees of freedom. 
For balanced data, ν can be estimated by the Satterthwaite formula 
[14] and 𝐲𝐲𝐣𝐣 was the calculated concentration at jth level. After 
calculating the uncertainty through equation (12), we have used the 
following formula to build the uncertainty profile. 
�𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 ± 𝑘𝑘𝑘𝑘(𝑍𝑍𝑗𝑗 )� < 𝜆𝜆 Eq. 13 
Where 
k is a coverage factor. The choice of the factor k is based on the level 
of confidence desired. For an approximate level of confidence of 
95%, k = 2. 
Zj is the estimate of the mean results. 
λ is the acceptance limits. 
RESULTS  
Pre-validation study 
The study of validity of the Beer-Lambert is performed on four 
concentration ranges like (50-700) µg mL-1, (50-600) µg mL-1, (50-
500) µg mL-1 and (50-400) µg mL-1. table 2 shows the values of 
coefficient of determination R² obtained for each concentration 
range considered. While, the value of R² is approximately 95% in the 
range (50-400) µg mL-1, it is preferable to study the validation of 
bioanalytical method in the range (50-500) µg mL-1. 
 
Table 2: Values of coefficient of determination of different studied concentration ranges 








The experimental design for calibration standard solutions was 
prepared in three replicates for three series (three separated days) 
of analyses and five levels of concentration. Independent validation 
standard solutions were prepared in three replicates for three series 
(days) of analyses and six levels of concentration. 
In order to find a more appropriate model, namely that allows us to 
obtain a guarantee of future results included in the acceptance 
limits. We generated several models relating the absorbance to 
concentration. As a response function, the simple linear regression 
model has been selected. 
By using inverse prediction and based on the selected calibration 
model. The concentrations are calculated at each concentration 
level. Then, recovery (Bias %), repeatability (RSDrep). Intermediate 
precision (RSDPI) and upper-lower β-expectation tolerance intervals 
are calculated at each concentration level and summarized in table 3. 
The accuracy of a bioanalytical method is represented by the 
accuracy profile illustrated in Fig. 2. 
 
Table 3: Results of the trueness, precision and accuracy for the validation of the assay method of acetaminophen in human plasma before 
the introduction of the correction factor 
Response function: linear 
simple 
  Series #1 Series #2 Series #3     
Slope 0.0012 0.0013 0.0013     
(p= 3; n= 3; m= 6) Intercept 0.1783 0.1787 0.1737     
R² 93.55 96.08 95.78     
  
Concentration level µg mL-1 













50 18.69 118.69 10.41 14.07 -8.94 46.33 
100 -21.49 78.51 10.56 11.51 -35.23 -7.75 
200 -9.31 90.69 6.64 9.03 -22.89 4.27 
300 -16.55 83.45 4.19 5.65 -23.81 -9.29 
400 -5.24 94.76 0.85 3.06 -13.10 6.25 
500 -16.31 83.69 2.48 3.68 -21.23 -11.40 
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As can be seen from table 3, the results show a lack of accuracy. The fig. 2 shows a gap between the accuracy profile (the upper and lower β-
expectation tolerance limits) and the acceptability limits that have been set at ±20%. This gap was due to the biological matrix effect. 
 
Fig. 2: Accuracy profile of the assay method of acetaminophen in human plasma before the introduction of the correction factor, the 
values of β-expectation and acceptance limits are set to 80% and 20% respectively 
 
In order to correct this matrix effect, a correction coefficient has 
been computed from the linearity equation slope linking the 
introduced theoretical concentrations to the recovered 
concentrations computed by inverse prediction. The applied 
correction coefficient corresponds to the inverse of the slope 
achieved with the validation standards. 
On the fig. 3 is plotted the regression line of calculated 
concentrations versus introduced concentrations. The equation of 
the straight line obtained is Z = 6.699 + 0.861X. The correction 
coefficient (CC) to be applied to the calculated concentrations is thus 
of CC =1/0.861, i. e. CC = 1.16. 
A new accuracy profile computation is carried out taking the 
correction coefficient into account. The correction is carried out on 
the validation data responses. As illustrated in fig. 4, the new 
accuracy profile obtained after correction coefficient shows that the 
method was only valid on a part of the studied application range. 
Indeed, the accuracy profile lower limit on the first and second level 
of concentration is beyond the acceptable limit set at ± 20%.   
 
Fig. 3: Straight regression of concentrations introduced versus calculated concentrations, the correction coefficient is looked as the 
inverse of slope the equation of the straight 
 
 
Fig. 4: Accuracy profile of the assay method of acetaminophen in human plasma after correction, the values of β-expectation and 
acceptance limits are set to 80% and 20% respectively 
 
In other hand, the lower and higher quantification limits 
computation from the accuracy profile of fig.4 were respectively 
100.34 µg mL-1 and 500 µg mL-1.  
Table 4 summarized the results obtained after correction for the 
whole set of concentration levels. 
Uncertainty profile 
Recently, an approach of uncertainty profile was developed by Saffaj 
and Ihssane. It’s based on compute of uncertainty on each 
concentration level using the upper and lower β-content, γ-
confidence tolerance interval. In this paper, we try to explain and 
detail the procedure for computing the two sided (β, γ)-content 
tolerance intervals for balanced one-way random effects models by 
using Mee’s method. For validation standards six concentration 
levels have involved in experiment design, all prepared in plasma. 
Each validation sample was analyzed three times (n= 3) for three 
different days (a= 3). The calibration plan was of type 5 x 3 x 3 and 
the response function chosen was the linear regression. 
Since the FDA recommends the 4-6-λ rule for the validation of 
bioanalytical methods [25,36,37], we set a value of β = 66.7% of the 
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content preferred to be compliant, the population of future 
measures included within the acceptance limits with a confidence 
level set at γ = 90%.  
Two Sided Content Tolerance Limits 
• For the first concentration level (Xj=1 = 50µg), one way ANOVA 
test was applied to calculate firstly MSe = 51.57 and MSb = 179.32. 
and secondly to get the estimation of the within-condition variance 
Sw
2 = 51.57 and of the between-condition variance Sb
2 = 92.85. 
• The quantile F is the mean square ratio: 𝐹𝐹 = 𝑀𝑀𝑀𝑀𝑏𝑏 𝑀𝑀𝑀𝑀𝑒𝑒⁄  i. e. F= 3.48 
• Fη is the 100η percentile of an F distribution with ν1 = a(n− 1) 
and ν2 = (a − 1): 
Fη = icdf[loi de Fisher; 1 − 0.85; 3 × (3− 1); (3− 1)] with η = 0.85 if 
γ = 0.90. i. e. Fη = 5.988 
With icfd is the inverse cumulative density function 
• The first report was R = max⁡[0; �F × Fη − 1 n⁄ �].  
Since [(F × Fη) − 1] n⁄ =  [(3.48 × 5.988)− 1] 3 = 6.61⁄ , the first 
report R = 6.61. 
• The second report wasR0 =
R+1
nR+1
 i. e. 
R0 = (6.61 + 1) [(3 ×⁄ 6.61) + 1] = 0.73.  
• The non-centrality parameter h = 1 (a × n × R0)⁄  i. e. 
h = 1 (3 × 3 × 0.73)⁄ = 0.304. 
• The β quantile of a non-central chi-square distribution χ(1;β)
2 (h) 
was calculated based on ν= 1; β = 0.667 and non-centrality 
parameter h = 0.304 i. e. χ(1;β)
2 (h) = 1.2499 
• The quantile chi-square χf;1−γ
2  was calculated based on f = 2.395 
and 1- γ = 0.1 i. e. χf;1−γ
2 = 0.342  
With f is the degrees of freedom calculated using formula 10. 
• The tolerance factor KS was calculated as:  




= (2.395 × 1.2499 0.342⁄ )−1/2
= 2.959 
• The lower and upper tolerance interval (L1; U1): 
L1 = Z1 − (KS × SPI) 
U1 = Z1 + (KS × SPI) 
With Z1 is the average of calculated concentrations equal to 68.95 µg 
mL-1 and SPI





i. e. SPI = (51.57 + 92.85)−1/2 = 9.7. 
Then, the (66.7%, 90%) content tolerance interval for the first 
concentration level (L1; U1) is [40.24; 97.65]. The calculation of 
lower-upper (β, γ)-content tolerance intervals of other 
concentrations levels (such as 100, 200, 300, 400 and 500 µg mL-1) 
are summarized in table 5. 
 




  Series #1 Series #2 Series #3     
Slope 0.00121 0.00127 0.00127     
(a=3; n=3; m=6) intercept 0.17834 0.17873 0.17371     
R² 93.55 96.08 95.78     
  
Concentration level µg mL-1 













50 37.90 137.90 10.41 14.07 70.00 5.80 
100 -8.78 91.22 10.56 11.51 7.18 -24.75 
200 3.91 103.91 6.64 9.03 16.53 -8.71 
300 -3.05 96.95 5.02 5.65 5.39 -11.49 
400 6.54 106.54 3.09 3.09 15.65 -2.57 
500 -2.77 97.23 2.97 3.68 2.94 -8.49 
 




















2.395 1.250 0.342 2.958 68.949 9.703 40.24 97.66 
2.904 1.218 0.543 2.552 91.216 10.496 64.43 118.0 
2.387 1.251 0.339 2.968 210.729 19.036 154.24 267.22 
2.775 1.224 0.489 2.636 290.864 16.436 247.54 334.18 
2.040 1.280 0.223 3.423 440.383 13.457 394.31 486.45 
2.532 1.240 0.393 2.827 486.139 17.870 435.62 536.66 
 
Uncertainty limits 
In order to estimate of uncertainty value at each concentration level 
according the formula 12, we need to calculate the quantile t(ν) of 
student which is the (1+γ)/2 quantile of the student t distribution 
with ν degrees of freedom. For balanced data ν(a. n. R∗) can be 
estimated by the Satterthwaite formula (Eq.10). 
The computation of the uncertainty as well as the two sided 
uncertainty limits for the first concentration level (𝑋𝑋𝑗𝑗=1 = 50µ𝑔𝑔) is 
given as follows:  




− 1) i. e. 
R∗ = 1 3⁄ ((179.32 51.57)⁄ − 1) = 0.826 
• The value of ν(a. n. R∗) was ν = (R∗ + 1)²/[(R∗ + 1 n⁄ )²/(a− 1) +
(1− 1 n⁄ )/(an)] 
i. e. ν = (0.826 + 1)^2/[(0.826 + 1 ⁄ 3)^2/(3− 1) + (1− 3)/(3 ×
3)]  = 4.469 
• The quantile t(ν) was 𝑡𝑡 = icdf�loi de student; 1+0.9
2
; 4.469�. i. e. 
t = 2.069 
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• The uncertainty u(Xj=1) was u = U1 − L1 2 × t(f∗)⁄  i. e. u(Xj=1) =
(97.65− 40.24) (2 × 2.069) =⁄ 13.88 µg mL−1 
• The expended uncertainty U(Xj=1) was U = k ∗ u(Xj=1) i. e. 
U(Xj=1) = 2 ∗ 13.87 = 27.75 µg mL
−1 
The choice of the factor k= 2 is based on the level of confidence of 95% 
• The two sided uncertainty limits is given by  
Zj=1 ±  U(Xj=1) = 68.95 ±  27.75 i. e. (96.70; 41.20) 
Equivalently, the interval can be expressed as following:  
(Bias ± U(Xj=1))/Xj=1 × 100 i. e. [(68.95− 50) ± 27.75 ]/50 × 100 = 
(95.31%; -19.52%)  
The computation of two sided uncertainty limits for the remaining 
concentrations level were performed using the same procedure and 
are given in table 6. 
 
Table 6: Calculation results of the measurement uncertainty and the two uncertainty limits for validation the assay method of 

























50.00 4.47 2.07 13.88 27.75 55.50 68.95 -19.51 95.31 
100.00 6.73 1.91 14.05 28.10 28.10 91.22 -35.56 17.99 
200.00 3.07 2.33 13.32 26.65 13.32 210.73 -11.61 19.43 
300.00 6.30 1.93 22.49 44.97 14.99 290.86 -17.49 11.40 
400.00 4.69 2.04 23.19 46.38 11.60 440.38 -5.31 18.40 
500.00 5.23 2.00 25.31 50.62 10.12 486.14 -12.88 7.33 
The upper and lower uncertainty limits expressed in relative value (%) are presented in Fig. 5 as a function of the introduced concentrations. As can 
be seen from the results, the method was considered valid since the uncertainty intervals are included in the ±20% acceptance limits for all the 
concentration levels tested except the two first concentrations levels (50 and 100 µg mL-1). 
 
 
Fig. 5: Uncertainty Profile for method validation for the determination of acetaminophen in human plasma, Beta is taken equal to 66.7% 
with a confidence level of 90% and the acceptance limits set at 20% 
 
DISCUSION 
On the basis of these results, it clearly appears the excellence and the 
power of the approach of the total error whatsoever approach 
accuracy profile or profile of uncertainty in assessing the 
performance of the bioanalytical method proposed. 
The efficiency of the proposed tool is summarized by the following 
points:  
The experimental design prepared and followed to perform 
validation consists of calibration range and a range of validation; 
both scales are repeated at each level of concentration in the 
different series.  
Repetition by the level of concentration under the conditions of 
precision intermediate used to estimate both the two types of error 
bias and precision. 
The calibration range, serves as a tool to generate multiple 
calibration models, the profile obtained allow to select the 
appropriate model.  
The decision, in conventional approaches, is taken based on the 
hypothesis test H0 looking separately the two errors: the bias and 
precision. In contrast, the total error approach, errors are combined 
to build a bilateral interval one expects will contain a proportion of 
future measures included in the acceptance limit, which is perfect 
with the main objective of an analytical method. 
The profile built, is not only a simple and easy tool for decision-making 
with respect to the validity of the studied method, as well as it let also to 
identify graphically the limit quantification. 
The approach of total error shows also its efficiency since it allows to 
assess the uncertainty using data derived from the validation study. 
Furthermore, there was a significant remark about a comparison 
between the approach using β-expectation tolerance interval and 
the approach of β,γ-content tolerance interval. Indeed, in the first 
approach, the parameter β expresses at once the accepted 
proportion of future measures and the probability indicating the 
level of confidence (the risk taken is 1-β). 
However, in the second, the proportion and risk are separated, as well β 
indicates the proportion (content) future acceptable measures and γ 
expresses the level of confidence (risk taken equal to 1-γ). 
This separation between the proportion and risk reveals a 
characteristic of important flexibility of approach of β,γ-content 
tolerance interval. Indeed, the change in values of (β, γ) gives 
analysts a wide choice to validate their method. 
Finally, to assess the reliability of the proposed bioanalytical 
method, validation is an essential step to accomplish, but not 
sufficient if one is to interpret the results correctly. Therefore, the 
uncertainty must be computed to guarantee the quality of the results 
obtained. For that reason, we have introduced in this paper a 
measurement of uncertainty in the validation step because it can 
yield an indication of the quality of the result. This information is 
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important for analysts who want to exploit this result to make 
critical decisions. 
CONCLUSION 
For the selected bioanalytical spectrometric method, we have 
managed to assess their performance by applying both important 
approaches based on total error concept: the accuracy profile and 
the uncertainty profile. 
The application of the accuracy profile approach founded on the β-
expectation tolerance intervals has led to plausible results allowing 
to judge that the bioanalytical method is valid over the range of 
[100.34; 500] µm mL-1, since the upper and lower 90%-expectation 
tolerance limits have fallen within the two acceptance limits of ± 
20%. Obviously, after the introduction of the correction coefficient 
which is worth 1.16. Using the uncertainty profile approach based 
on (β, γ)- content tolerance intervals has also shown its effectiveness 
to verify the performance of the spectrophotmetric method, since 
the "two - sided 66.7%-content, 90% -confidence tolerance intervals 
"are found within two acceptance limits of ± 20% over the range of 
[170; 500] µm mL-1. 
The excellence of the uncertainty profile approach showed itself, 
when verifying the validity of the bioanalytical method, first by 
calculation of the measurement uncertainty at each level of 
concentration as a decision tool and second because this approach 
gives the flexibility to change the values of β-content and γ-
confidence as required by the analyst or the government regulations.  
Finally, the overall results obtained allow the demonstration of the 
successful applying of the total error approach. In fact, both the 
uncertainty profile and the accuracy profile are able to be applied to 
validate the analytical and bioanalytical methods and show their 
performance and their suitability for use in routine quality control. 
On the other hand, this approach makes also possible the estimation 
of the measurement uncertainty of the method without any 
additional efforts, by using data coming from the analytical 
validation when we respect as best as possible the intermediate 
precision conditions at each concentration level. 
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